STATE-OF-THE-ART PAPER
Inflammation, Growth Factors, and Pulmonary Vascular Remodeling
Paul M. Hassoun, MD*,*,
Luc Mouthon, MD, PhD ,
Joan A. Barberà, MD ,
Saadia Eddahibi, PhD ,
Sonia C. Flores, PhD||,
Friedrich Grimminger, MD, PhD¶,
Peter Lloyd Jones, PhD#,
Michael L. Maitland, MD, PhD**,
Evangelos D. Michelakis, MD,
Nicholas W. Morrell, MA, MD,
John H. Newman, MD,
Marlene Rabinovitch, MD||||,
Ralph Schermuly, PhD¶¶,
Kurt R. Stenmark, MD##,
Norbert F. Voelkel, MD***,
Jason X.-J. Yuan, MD, PhD and
Marc Humbert, MD, PhD
* Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland
Department of Internal Medicine, Cochin Hospital, Paris-Descartes University, Paris, France
Servei de Pneumologia, Hospital Clinic, Universitat de Barcelona, and CIBERES, Barcelona, Spain
Departement de Physiologie, Hôpital Henri Mondor, Créteil, France
|| Division of Pulmonary Sciences & Critical Care Medicine, University of Colorado, Denver, Colorado
¶ Medical Clinic IV and V, University Hospital Giessen and Marburg GmbH, Giessen, Germany
# University of Pennsylvania, Penn/CMREF Center for Pulmonary Arterial Hypertension Research, Philadelphia, Pennsylvania
** Section of Hematology/Oncology, Department of Medicine and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois
Pulmonary Hypertension Program, University of Alberta Hospital, Edmonton, Alberta, Canada
Pulmonary Vascular Diseases Unit, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
Department of Medicine, Division of Pulmonary/Allergy/Immunology, Vanderbilt University Medical Center, Nashville, Tennessee
|||| The Wall Center for Pulmonary Vascular Diseases, Stanford University School of Medicine, Stanford, California
¶¶ Department of Internal Medicine, Justus-Liebig University of Giessen, Giessen, Germany
## Developmental Lung Biology Laboratory, University of Colorado at Denver and Health Sciences Center, Denver, Colorado
*** Pulmonary and Critical Care Division, Virginia Commonwealth University, Richmond, Virginia
Department of Medicine, University of California San Diego, La Jolla, California
Université Paris-Sud, Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine Béclère, Clamart, France
Manuscript received February 6, 2009;
accepted April 15, 2009.
* Reprint requests and correspondence: Dr. Paul M. Hassoun, Professor of Medicine, Johns Hopkins University Department of Medicine, Pulmonary and Critical Care Medicine, 1830 East Monument Street, Room 530, Baltimore, Maryland 21287 (Email: phassoun{at}jhmi.edu).
Inflammatory processes are prominent in various types of human and experimental pulmonary hypertension (PH) and are increasingly recognized as major pathogenic components of pulmonary vascular remodeling. Macrophages, T and B lymphocytes, and dendritic cells are present in the vascular lesions of PH, whether in idiopathic pulmonary arterial hypertension (PAH) or PAH related to more classical forms of inflammatory syndromes such as connective tissue diseases, human immunodeficiency virus (HIV), or other viral etiologies. Similarly, the presence of circulating chemokines and cytokines, viral protein components (e.g., HIV-1 Nef), and increased expression of growth (such as vascular endothelial growth factor and platelet-derived growth factor) and transcriptional (e.g., nuclear factor of activated T cells or NFAT) factors in these patients are thought to contribute directly to further recruitment of inflammatory cells and proliferation of smooth muscle and endothelial cells. Other processes, such as mitochondrial and ion channel dysregulation, seem to convey a state of cellular resistance to apoptosis; this has recently emerged as a necessary event in the pathogenesis of pulmonary vascular remodeling. Thus, the recognition of complex inflammatory disturbances in the vascular remodeling process offers potential specific targets for therapy and has recently led to clinical trials investigating, for example, the use of tyrosine kinase inhibitors. This paper provides an overview of specific inflammatory pathways involving cells, chemokines and cytokines, cellular dysfunctions, growth factors, and viral proteins, highlighting their potential role in pulmonary vascular remodeling and the possibility of future targeted therapy.
Key Words: growth factors • inflammation • pulmonary vascular remodeling
|
Abbreviations and Acronyms
| | AECA = anti-endothelial cell antibody | | bcl = B-cell lymphoma | | COPD = chronic obstructive pulmonary disease | | EC = endothelial cell | | EGF = epidermal growth factor | | ET = endothelin | | HCV = hepatitis C virus | | HHV = human herpes virus | | HIV = human immunodeficiency virus | | 5-HT = serotonin | | 5-HTT = serotonin transporter | | IL = interleukin | | IPAH = idiopathic pulmonary arterial hypertension | | Kv = voltage-dependent potassium channel | | MCT = monocrotaline | | mRNA = messenger ribonucleic acid | | NFAT = nuclear factor of activated T cells | | PA = pulmonary artery | | PAH = pulmonary arterial hypertension | | PCR = polymerase chain reaction | | PDGF = platelet-derived growth factor | | PDGFR = platelet-derived growth factor receptor | | PH = pulmonary hypertension | | RV = right ventricular | | SIV = simian immunodeficiency virus | | SMC = smooth muscle cell | | SSc = systemic sclerosis | | TGF = transforming growth factor | | TN = tenascin | | TNF = tumor necrosis factor | | VEGF = vascular endothelial growth factor |
|
This article has been cited by other articles:
|
|
|
|
 
R. M. Tuder, L. A. Davis, and B. B. Graham
Targeting Energetic Metabolism: A New Frontier in the Pathogenesis and Treatment of Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
February 1, 2012;
185(3):
260 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Yeager, D. D. Belchenko, C. M. Nguyen, K. L. Colvin, D. D. Ivy, and K. R. Stenmark
Endothelin-1, the Unfolded Protein Response, and Persistent Inflammation: Role of Pulmonary Artery Smooth Muscle Cells
Am. J. Respir. Cell Mol. Biol.,
January 1, 2012;
46(1):
14 - 22.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Price, S. J. Wort, F. Perros, P. Dorfmuller, A. Huertas, D. Montani, S. Cohen-Kaminsky, and M. Humbert
Inflammation in Pulmonary Arterial Hypertension
Chest,
January 1, 2012;
141(1):
210 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Churg, S. Zhou, and J. L. Wright
Matrix metalloproteinases in COPD
Eur. Respir. J.,
January 1, 2012;
39(1):
197 - 209.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Shreiner, B. J. Murdock, A. A. Sadighi Akha, N. R. Falkowski, P. J. Christensen, E. S. White, C. M. Hogaboam, and G. B. Huffnagle
Repeated Exposure to Aspergillus fumigatus Conidia Results in CD4+ T Cell-Dependent and -Independent Pulmonary Arterial Remodeling in a Mixed Th1/Th2/Th17 Microenvironment That Requires Interleukin-4 (IL-4) and IL-10
Infect. Immun.,
January 1, 2012;
80(1):
388 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weng, D. M. Baron, K. D. Bloch, A. D. Luster, J. J. Lee, and B. D. Medoff
Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol,
December 1, 2011;
301(6):
L927 - L936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Grader-Beck, F. Boin, S. von Gunten, D. Smith, A. Rosen, and B. S. Bochner
Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease
Ann Rheum Dis,
December 1, 2011;
70(12):
2218 - 2224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Zhao, C.-N. Chen, Z. Zhai, and M. R. Wilkins
Chapter 2 Pathobiology of pulmonary arterial hypertension
OCL Pulmonary Hypertension,
December 1, 2011;
1(1):
med-9780199572632-chapter - med-9780199572632-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Bussone, M. C. Tamby, C. Calzas, N. Kherbeck, Y. Sahbatou, C. Sanson, K. Ghazal, H. Dib, B. B. Weksler, C. Broussard, et al.
IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction
Ann Rheum Dis,
November 14, 2011;
(2011)
annrheumdis-2011-200195v1.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. Farkas and M. Kolb
Pulmonary Microcirculation in Interstitial Lung Disease
Proceedings of the ATS,
November 1, 2011;
8(6):
516 - 521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tamosiuniene, W. Tian, G. Dhillon, L. Wang, Y. K. Sung, L. Gera, A. J. Patterson, R. Agrawal, M. Rabinovitch, K. Ambler, et al.
Regulatory T Cells Limit Vascular Endothelial Injury and Prevent Pulmonary Hypertension
Circ. Res.,
September 30, 2011;
109(8):
867 - 879.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Tu, L. Dewachter, B. Gore, E. Fadel, P. Dartevelle, G. Simonneau, M. Humbert, S. Eddahibi, and C. Guignabert
Autocrine Fibroblast Growth Factor-2 Signaling Contributes to Altered Endothelial Phenotype in Pulmonary Hypertension
Am. J. Respir. Cell Mol. Biol.,
August 1, 2011;
45(2):
311 - 322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weng, M. J. Raher, P. Leyton, T. P. Combs, P. E. Scherer, K. D. Bloch, and B. D. Medoff
Adiponectin Decreases Pulmonary Arterial Remodeling in Murine Models of Pulmonary Hypertension
Am. J. Respir. Cell Mol. Biol.,
August 1, 2011;
45(2):
340 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Dweik and S. C. Erzurum
Update on Pulmonary Vascular Diseases 2010
Am. J. Respir. Crit. Care Med.,
July 1, 2011;
184(1):
26 - 31.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Farkas, J. Gauldie, N. F. Voelkel, and M. Kolb
Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis: A Tale of Angiogenesis, Apoptosis, and Growth Factors
Am. J. Respir. Cell Mol. Biol.,
July 1, 2011;
45(1):
1 - 15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-O. Larsen, A. Yndestad, I. Sjaastad, E. M. Loberg, I. L. Goverud, B. Halvorsen, J. Jia, A. K. Andreassen, C. Husberg, S. Jonasson, et al.
Lack of CCR7 induces pulmonary hypertension involving perivascular leukocyte infiltration and inflammation
Am J Physiol Lung Cell Mol Physiol,
July 1, 2011;
301(1):
L50 - L59.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Rhodes, J. Wharton, L. S. Howard, J. S. R. Gibbs, and M. R. Wilkins
Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension
Heart,
July 1, 2011;
97(13):
1054 - 1060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sukumaran, W. J. Jusko, D. C. DuBois, and R. R. Almon
Light-dark oscillations in the lung transcriptome: implications for lung homeostasis, repair, metabolism, disease, and drug action
J Appl Physiol,
June 1, 2011;
110(6):
1732 - 1747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Montani, M. Humbert, and R. Souza
Letter by Montani et al Regarding Article, "Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension"
Circulation,
May 31, 2011;
123(21):
e614 - e614.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. S. de Man, H. W. H. van Hees, M. L. Handoko, H. W. Niessen, I. Schalij, M. Humbert, P. Dorfmuller, O. Mercier, H.-J. Bogaard, P. E. Postmus, et al.
Diaphragm Muscle Fiber Weakness in Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
May 15, 2011;
183(10):
1411 - 1418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dumitrascu, C. Kulcke, M. Konigshoff, F. Kouri, X. Yang, N. Morrell, H. A. Ghofrani, N. Weissmann, R. Reiter, W. Seeger, et al.
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Eur. Respir. J.,
May 1, 2011;
37(5):
1104 - 1118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Meadows, M. G. Risbano, L. Zhang, M. W. Geraci, R. M. Tuder, D. H. Collier, and T. M. Bull
Increased Expression of Growth Differentiation Factor-15 in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Chest,
May 1, 2011;
139(5):
994 - 1002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Thenappan, A. Goel, G. Marsboom, Y.-H. Fang, P. T. Toth, H. J. Zhang, H. Kajimoto, Z. Hong, J. Paul, C. Wietholt, et al.
A Central Role for CD68(+) Macrophages in Hepatopulmonary Syndrome: Reversal by Macrophage Depletion
Am. J. Respir. Crit. Care Med.,
April 15, 2011;
183(8):
1080 - 1091.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Hassoun and R. Damico
Moving beyond the "Allegory of the Cave" in the assessment of pulmonary arterial hypertension
J Appl Physiol,
April 1, 2011;
110(4):
871 - 872.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. White, L. Loughlin, Z. Maqbool, M. Nilsen, J. McClure, Y. Dempsie, A. H. Baker, and M. R. MacLean
Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH
Physiol Genomics,
April 1, 2011;
43(8):
417 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Pluteanu and L. L. Cribbs
Regulation and function of Cav3.1 T-type calcium channels in IGF-I-stimulated pulmonary artery smooth muscle cells
Am J Physiol Cell Physiol,
March 1, 2011;
300(3):
C517 - C525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tian, S. Fratz, Y. Hou, Q. Lu, A. Gorlach, J. Hess, C. Schreiber, S. A. Datar, P. Oishi, J. Nechtman, et al.
Delineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease
Physiol Genomics,
January 20, 2011;
43(2):
87 - 98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Erzurum, S. I. Rounds, T. Stevens, M. Aldred, J. Aliotta, S. L. Archer, K. Asosingh, R. Balaban, N. Bauer, J. Bhattacharya, et al.
Strategic Plan for Lung Vascular Research: An NHLBI-ORDR Workshop Report
Am. J. Respir. Crit. Care Med.,
December 15, 2010;
182(12):
1554 - 1562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Jardim, S. Hoette, and R. Souza
Contemporary issues in pulmonary hypertension
Eur. Respir. Rev.,
December 1, 2010;
19(118):
266 - 271.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Durrington, P. D. Upton, S. Hoer, J. Boname, B. J. Dunmore, J. Yang, T. K. Crilley, L. M. Butler, D. J. Blackbourn, G. B. Nash, et al.
Identification of a Lysosomal Pathway Regulating Degradation of the Bone Morphogenetic Protein Receptor Type II
J. Biol. Chem.,
November 26, 2010;
285(48):
37641 - 37649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. B. Abdul-Salam, J. Wharton, J. Cupitt, M. Berryman, R. J. Edwards, and M. R. Wilkins
Proteomic Analysis of Lung Tissues From Patients With Pulmonary Arterial Hypertension
Circulation,
November 16, 2010;
122(20):
2058 - 2067.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Schiess, O. Senn, M. Fischler, L. C. Huber, S. Vatandaslar, R. Speich, and S. Ulrich
Tobacco Smoke: A Risk Factor for Pulmonary Arterial Hypertension?: A Case-Control Study
Chest,
November 1, 2010;
138(5):
1086 - 1092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Dieude, M. Guedj, J. Wipff, B. Ruiz, G. Riemekasten, M. Matucci-Cerinic, I. Melchers, E. Hachulla, P. Airo, E. Diot, et al.
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population
Ann Rheum Dis,
November 1, 2010;
69(11):
1958 - 1964.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kumpers, N. Nickel, A. Lukasz, H. Golpon, V. Westerkamp, K. M. Olsson, D. Jonigk, L. Maegel, C. L. Bockmeyer, S. David, et al.
Circulating angiopoietins in idiopathic pulmonary arterial hypertension
Eur. Heart J.,
September 2, 2010;
31(18):
2291 - 2300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Galie, M. Palazzini, and A. Manes
Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses
Eur. Heart J.,
September 1, 2010;
31(17):
2080 - 2086.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wang, Z. Gong, A. Liang, Y. Xie, S.-L. Liu, Z. Yu, L. Wang, and Y. Wang
Compromised T-Cell Immunity and Virus-like Structure in a Patient with Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
August 1, 2010;
182(3):
434 - 435.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Le Pavec, M. Humbert, L. Mouthon, and P. M. Hassoun
Systemic Sclerosis-associated Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
June 15, 2010;
181(12):
1285 - 1293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Sutliff, B.-Y. Kang, and C. M. Hart
PPAR{gamma} as a potential therapeutic target in pulmonary hypertension
Therapeutic Advances in Respiratory Disease,
June 1, 2010;
4(3):
143 - 160.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. G. Elliott, R. J. Barst, W. Seeger, M. Porres-Aguilar, L. M. Brown, R. T. Zamanian, and L. J. Rubin
Worldwide Physician Education and Training in Pulmonary Hypertension: Pulmonary Vascular Disease: The Global Perspective
Chest,
June 1, 2010;
137(6_suppl):
85S - 94S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Wilkins, O. Ali, W. Bradlow, J. Wharton, A. Taegtmeyer, C. J. Rhodes, H. A. Ghofrani, L. Howard, P. Nihoyannopoulos, R. H. Mohiaddin, et al.
Simvastatin as a Treatment for Pulmonary Hypertension Trial
Am. J. Respir. Crit. Care Med.,
May 15, 2010;
181(10):
1106 - 1113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Dorfmuller, D. Montani, and M. Humbert
Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension
Eur. Respir. J.,
January 1, 2010;
35(1):
6 - 8.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hansmann and M. Rabinovitch
The protective role of adiponectin in pulmonary vascular disease
Am J Physiol Lung Cell Mol Physiol,
January 1, 2010;
298(1):
L1 - L2.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hansmann and R. T. Zamanian
PPAR{gamma} Activation: A Potential Treatment For Pulmonary Hypertension
Science Translational Medicine,
December 23, 2009;
1(12):
12ps14 - 12ps14.
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Task Force for the Diagnosis and Treatment of, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension
Eur. Respir. J.,
December 1, 2009;
34(6):
1219 - 1263.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Frid, M. Li, M. Gnanasekharan, D. L. Burke, M. Fragoso, D. Strassheim, J. L. Sylman, and K. R. Stenmark
Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall
Am J Physiol Lung Cell Mol Physiol,
December 1, 2009;
297(6):
L1059 - L1072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Eur. Heart J.,
October 2, 2009;
30(20):
2493 - 2537.
[Full Text]
[PDF]
|
|
|
|
